Skip to main content

Peer Review reports

From: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Original Submission
26 Dec 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
23 Mar 2022 Reviewed Reviewer Report
28 Mar 2022 Reviewed Reviewer Report - Matthew Chan
14 Apr 2022 Author responded Author comments - Chuanliang Cui
Resubmission - Version 3
14 Apr 2022 Submitted Manuscript version 3
15 Apr 2022 Author responded Author comments - Chuanliang Cui
Resubmission - Version 4
15 Apr 2022 Submitted Manuscript version 4
18 Apr 2022 Author responded Author comments - Chuanliang Cui
Resubmission - Version 5
18 Apr 2022 Submitted Manuscript version 5
30 Apr 2022 Author responded Author comments - Chuanliang Cui
Resubmission - Version 6
30 Apr 2022 Submitted Manuscript version 6
Publishing
9 May 2022 Editorially accepted
20 May 2022 Article published 10.1186/s12885-022-09663-5

You can find further information about peer review here.

Back to article page